Alto Neuroscience, Inc. ANRO
NYSE
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -77.17% | -56.09% | -72.96% | -6.45% | 15.50% |
| Total Depreciation and Amortization | 10.37% | 8.88% | 7.60% | -7.65% | 34.43% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 56.10% | 64.51% | 8.19% | 26.06% | 30.39% |
| Change in Net Operating Assets | -114.42% | 181.24% | 5.71% | 2,021.21% | -53.45% |
| Cash from Operations | -109.28% | -43.41% | -63.63% | 11.56% | 15.42% |
| Capital Expenditure | -- | -- | -2,216.67% | 100.00% | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -2,216.67% | 100.00% | 100.00% |
| Total Debt Issued | -- | -- | -- | -- | -100.00% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 63,243.79% | -- | 60,509.09% | 102,659.18% | 128.36% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -154.01% | -792.86% | -- | -- |
| Cash from Financing | 62,883.66% | -144.54% | 1,159.35% | 102,318.37% | -88.38% |
| Foreign Exchange rate Adjustments | 150.00% | 233.33% | 27.27% | -116.67% | 42.86% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 873.99% | -52.09% | 1,267.60% | 387.02% | 14.46% |